Primary Care Clinics in Ishpeming, MI Accepting Medicare
3 Primary Care Clinics found. Showing 1 - 3
 Bell Medical Center Clinic/Center - Multi-Specialty Medicare: Not Enrolled in Medicare Practice Location: 901 Lakeshore Dr, Ishpeming, MI 49849 Phone: 906-485-2143 Fax: 906-486-6898 |
Jpp Management Of Negaunee Llc Clinic/Center - Primary Care Medicare: Not Enrolled in Medicare Practice Location: 1000 Country Ln Ste 300, Ishpeming, MI 49849 Phone: 906-361-3154 |
Bell Physician Practices Inc Family Medicine Medicare: Medicare Enrolled Practice Location: 901 Lakeshore Dr, Ishpeming, MI 49849 Phone: 615-372-8500 |
News Archive
Miracor's PICSO System may help advance heart failure treatment
Miracor Medical Systems GmbH announced today that its PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) System, designed to improve outcomes for acute coronary syndrome (ACS) and heart failure patients, has been cited as a technology that "may advance heart failure (HF) treatment significantly".
CARES Act helped reduce social interaction of viral spread
As case rates of COVID-19 reach new heights across the nation, many states and cities are tightening stay-at-home restrictions to stop the spread.
Positive results from Biotron's BIT225 Phase 2a trial on HCV
Australian drug development company Biotron Limited has released headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 in Hepatitis C virus (HCV) infected patients.
Swimmer's ear costs millions in healthcare each year: CDC report
Swimmer's ear (otitis externa) is a common infection that accounts for almost $500 million in U.S. health-care costs each year, according to a new government report. The report from the U.S. Centers for Disease Control and Prevention, published in the agency's May 20 Morbidity and Mortality Weekly Report, says this condition results in 2.4 million doctor visits annually in the United States, each visit costing an average of $200.
Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab
Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.
› Verified 6 days ago